Significance of Decreasing Rate of HIV and HBV Co-infection in a Nationwide Korean HIV/AIDS Cohort

Kim, Yoonjung; Kim, Shin‐Woo; Kwon, Ki Tae; Chang, Hyun Ha; Jun, Yoonhee; Park, Dae Won; Song, Joon Young; Choi, Jun Yong; Kim, Hyo Youl; Kim, June Myung; Choi, Bo Youl; Choi, Yunsu; Kee, Mee Kyung; Yoo, Myeong Su; Lee, Jung‐Kyu

doi:10.3346/jkms.2020.35.e7

Cited by 4 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, a study of two moderate COVID-19 patients revealed that viral loads peaked at 3 to 5 days from first symptom onset and slowly decreased until the second week. Additionally, virus was detected in their lower respiratory systems before lower respiratory symptoms occurred [88]. More recent studies showed similar results.…”

Section: Differencse In Viral Load Between Mild and Severe Covid-19 Patientssupporting

confidence: 57%

Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics

Choi

Moon

Yang

et al. 2021

IJMS

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, has become a worldwide pandemic. Symptoms range from mild fever to cough, fatigue, severe pneumonia, acute respiratory distress syndrome (ARDS), and organ failure, with a mortality rate of 2.2%. However, there are no licensed drugs or definitive treatment strategies for patients with severe COVID-19. Only antiviral or anti-inflammatory drugs are used as symptomatic treatments based on clinician experience. Basic medical researchers are also trying to develop COVID-19 therapeutics. However, there is limited systematic information about the pathogenesis of COVID-19 symptoms that cause tissue damage or death and the mechanisms by which the virus infects and replicates in cells. Here, we introduce recent knowledge of time course changes in viral titers, delayed virus clearance, and persistent systemic inflammation in patients with severe COVID-19. Based on the concept of drug reposition, we review which antiviral or anti-inflammatory drugs can effectively treat COVID-19 patients based on progressive symptoms and the mechanisms inhibiting virus infection and replication.

show abstract

Section: Differencse In Viral Load Between Mild and Severe Covid-19 Patientssupporting

confidence: 57%

Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics

Choi

Moon

Yang

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…However, unlike findings from previous studies, our findings suggest that there was no significant increase in liver cancer caused by hepatitis B or C infection and lung cancer caused by smoking or pulmonary diseases in people with HIV in Korea. The prevalence of hepatitis B infection in a Korean HIV/AIDS cohort, including approximately 10% of people infected with HIV in Korea, was 5.2%, which was similar to that of the general population of men in Korea (4%-5%) . The prevalence of current smoking was comparable between individuals infected with HIV (42.8%) and Korean men (49.8%) .…”

Section: Discussionmentioning

confidence: 70%

“…Incident Cancer Cases and Incidence Rate of Cancer in Patients With HIV Infection 20 to 79 Years of Age in Korea, 2006-2018Cancer Incidence Among Adults With HIV in a Population-Based Cohort in Korea smoking or pulmonary diseases in people with HIV in Korea. The prevalence of hepatitis B infection in a Korean HIV/AIDS cohort, including approximately 10% of people infected with HIV in Korea,18 …”

mentioning

confidence: 99%

Cancer Incidence Among Adults With HIV in a Population-Based Cohort in Korea

et al. 2022

Self Cite

View full text Add to dashboard Cite

IMPORTANCEIn combination with a decreased risk of AIDS-defining cancers and improved survival of people infected with HIV, the burden of non-AIDS-defining cancer has increased markedly.Although a substantial number of studies have measured the cancer risk among people with HIV in developed countries, little research has been conducted on the risk of cancer in HIV-infected people in Asia. OBJECTIVE To examine the cancer incidence and the estimated risk of cancer among people in Korea infected with HIV compared with the general population.

show abstract

“…Reductions were also observed in South Korea and Taiwan; the prevalence of HBV in South Korea decreased from 8% to 3.7% after neonatal vaccination was introduced [13]. It also reduced in people living with HIV, from 8.8% for those born between 1960 and 1964 to 0% for those born between 1995 and 1999 [14]. In Taiwan, the rate of HIV‐HBV co‐infection in people living with HIV decreased from 18.1% in those born before the vaccination programme was introduced in July 1986 to 3.4% in those born after [15].…”

Section: Routes Of Transmissionmentioning

confidence: 99%

Current practice and recommendations for management of hepatitis B virus in people living with HIV in Asia

Lui,

Wong,

Yang

et al. 2023

HIV Medicine

View full text Add to dashboard Cite

BackgroundThe prevalence of HIV and hepatitis B virus (HBV) co‐infection is higher in Asia than in Europe and North America and varies significantly between different regions within Asia. Important routes of transmission of both these infections include high‐risk unprotected sexual contact, intravenous drug use, and transmission of maternal infection perinatally or in early childhood. While life expectancy among people living with HIV has been extended with effective antiretroviral therapy (ART), HBV‐induced liver injury and complications have emerged as a leading cause of morbidity and mortality in people living with HIV.ObjectivesThis article describes the prevalence of co‐infection, current clinical practice, and recommendations for the management of people living with HIV‐HBV co‐infection in Asia.Results and ConclusionsScreening for HBV should occur at the time of HIV diagnosis; however, HBV screening rates in people living with HIV in Asia vary widely by region. Similarly, people with HBV should be screened for HIV before initiation of HBV antiviral therapy. People with HIV‐HBV co‐infection should be assessed for liver damage and risk factors for liver disease and be monitored regularly for liver complications and HBV DNA. Medical treatment with ART is lifelong and includes tenofovir and lamivudine or emtricitabine, unless intolerant or contraindicated, as these are active against both HIV and HBV. HBV vaccination programmes are effective in reducing co‐infection rates. Mother‐to‐child transmission can be prevented through measures such as vaccination, antenatal screening, and treatment of pregnant women who are infected.

show abstract

Significance of Decreasing Rate of HIV and HBV Co-infection in a Nationwide Korean HIV/AIDS Cohort

Cited by 4 publications

References 21 publications

Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics

Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics

Cancer Incidence Among Adults With HIV in a Population-Based Cohort in Korea

Current practice and recommendations for management of hepatitis B virus in people living with HIV in Asia

Contact Info

Product

Resources

About